Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NC-001
- Development stage
- Preclinical
- Lead developer
- NodCure
- Modality
- Small Molecules
01
Overview
NC-001 is a small molecule therapeutic candidate being developed by NodCure for the treatment of cancer metastasis, mucositis, and ulcerative colitis. Currently in the IND-enabling phase, NC-001 is designed to modulate the Nucleotide-binding oligomerization domain (NOD) signaling pathway. By targeting NOD-like receptors (NLRs), the drug aims to regulate the inflammatory environment and immune responses that drive the progression of metastatic cancer and chronic inflammatory diseases of the gastrointestinal tract. The candidate is the lead therapeutic in NodCure's pipeline and is being advanced toward clinical trials for multiple high-need indications.
Beyond the preview
Go deeper on NC-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NC-001.